Bicycle Therapeutics plc
BCYC
Price:
$24.2724
Market Cap:
$1.67B
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a...[Read more]
Industry
Biotechnology
IPO Date
2019-05-23
Stock Exchange
NASDAQ
Ticker
BCYC
The ROE as of September 2024 (TTM) for Bicycle Therapeutics plc (BCYC) is -32.80%
According to Bicycle Therapeutics plc’s latest financial reports and current stock price. The company's current ROE is -32.80%. This represents a change of 252.28% compared to the average of -9.31% of the last 4 quarters.
Bicycle Therapeutics plc (BCYC) Historical ROE (quarterly & annually)
How has BCYC ROE performed in the past?
The mean historical ROE of Bicycle Therapeutics plc over the last ten years is -37.32%. The current -32.80% ROE has changed -12.09% with respect to the historical average. Over the past ten years (40 quarters), BCYC's ROE was at its highest in in the December 2018 quarter at 9.51%. The ROE was at its lowest in in the September 2018 quarter at -26.87%.
Average
-37.32%
Median
-37.23%
Minimum
-168.37%
Maximum
34.46%
Bicycle Therapeutics plc (BCYC) ROE by Quarter and Year
Discovering the peaks and valleys of Bicycle Therapeutics plc ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 115.71%
Maximum Annual ROE = 34.46%
Minimum Annual Increase = -204.97%
Minimum Annual ROE = -168.37%
| Year | ROE | Change |
|---|---|---|
| 2023 | -48.71% | 17.01% |
| 2022 | -41.63% | 115.71% |
| 2021 | -19.30% | -63.89% |
| 2020 | -53.44% | 62.71% |
| 2019 | -32.84% | -204.97% |
| 2018 | 31.29% | -9.21% |
| 2017 | 34.46% | -120.47% |
Bicycle Therapeutics plc (BCYC) Average ROE
How has BCYC ROE performed in the past?
The current ROE of Bicycle Therapeutics plc (BCYC) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-36.54%
5-year avg
-39.18%
10-year avg
-37.32%
Bicycle Therapeutics plc (BCYC) ROE vs. Peers
How is BCYC’s ROE compared to its peers?
Bicycle Therapeutics plc’s ROE is greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Homology Medicines, Inc. (-100.91%), greater than Tenaya Therapeutics, Inc. (-80.97%), greater than IGM Biosciences, Inc. (-119.02%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Merus N.V. (-36.33%), less than Inhibrx, Inc. (1.62%), greater than immatics biotechnologies GmbH (-23.40%), greater than Seer, Inc. (-21.26%), greater than ORIC Pharmaceuticals, Inc. (-40.19%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Cullinan Oncology, Inc. (-28.37%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Adagene Inc. (-63.48%), greater than Acrivon Therapeutics, Inc. Common Stock (-47.31%), greater than Mineralys Therapeutics, Inc. (-42.61%),
| Company | ROE | Market cap |
|---|---|---|
| -20.53% | $3.13B | |
| -255.67% | $1.16B | |
| -86.28% | $325.85M | |
| -44.73% | $2.08B | |
| -100.91% | $3.02M | |
| -80.97% | $155.81M | |
| -119.02% | $888.59M | |
| -70.40% | $344.30M | |
| -57.89% | $776.29M | |
| -36.33% | $3.41B | |
| 1.62% | $253.94M | |
| -23.40% | $1.28B | |
| -21.26% | $103.82M | |
| -40.19% | $708.95M | |
| -122.97% | $54.20M | |
| -28.37% | $978.65M | |
| -44.60% | $438.56M | |
| -63.48% | $123.52M | |
| -47.31% | $262.33M | |
| -42.61% | $575.83M |
Build a custom stock screener for Bicycle Therapeutics plc (BCYC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bicycle Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Bicycle Therapeutics plc (BCYC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Bicycle Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Bicycle Therapeutics plc's ROE?
How is the ROE calculated for Bicycle Therapeutics plc (BCYC)?
What is the highest ROE for Bicycle Therapeutics plc (BCYC)?
What is the 3-year average ROE for Bicycle Therapeutics plc (BCYC)?
What is the 5-year average ROE for Bicycle Therapeutics plc (BCYC)?
How does the current ROE for Bicycle Therapeutics plc (BCYC) compare to its historical average?